The prevalence of pathogenic variants in the specific genes BRCA1 and BRCA2 in unselected breast cancer patients has been estimated to be 2–2.5% [1, 2], similarly to what has been reported in the Southern Swedish population [3]. This evidence concerns the gene BRCA2 and breast carcinoma.